Facing the new situation of Internet, capital, breeding and the development status of veterinary biological products industry, on the afternoon of the 16th, the biological products sub-forum of the veterinary drug industry development and animal product safety high-level forum set up face-to-face interactive activities. Chaired by Hu Qiyi, Chairman of China Animal Husbandry Industry Co., Ltd., Gu Hong, Director of the Pharmaceutical Administration Department of the Veterinary Administration of the Ministry of Agriculture, Li Wanmeng, Executive General Manager of Merial China, Sun Jinzhong, General Manager of Placo Bioengineering Co., Ltd., Beijing Zhongliankang Biotechnology Co., Ltd. Chairman Kuang Huixing, Chairman Sun Hao of Beijing Huaduyu Poultry Industry Co., Ltd., General Manager Wang Yongsheng, Jinyu Baoling Biopharmaceutical Co., Ltd., General Manager Fan Gencheng, Qingdao Yibang Biological Engineering Co., Ltd., and Wu Dongxun, China Animal Husbandry Industry Co., Ltd. The general manager participated in the communication session. In this session, representatives of various companies raised sharp questions, and they were all answered wonderfully by industry leaders and experts.

1. Perspective

Question: In the development of the biological products industry, as a regulator, can you examine from the perspective of the company, what needs to be improved or create more conditions for the company?

Hong Gu, Director of the Pharmaceutical Administration Department of the Veterinary Administration of the Ministry of Agriculture: "Before this year, the "Industry Guidance Opinions" will be issued, which will add content related to the reform of the new industry system. The next step will be revised one by one, and the system will be implemented. The reform system includes enterprises Concerned about the reform of the "Veterinary Drug Evaluation System", update the settings and refine the evaluation mechanism of veterinary drugs (registration categories of different veterinary drugs, different evaluation indicators), and reform the concept of new veterinary drugs, not "arbitrarily" eliminated, but changed Use scientific methods to evaluate the situation and contribute to the promotion of enterprise development.

2. The gap

Question: What is the gap between Chinese veterinary drugs and foreign countries?

Wang Yongsheng: In fact, there is no significant difference between our country’s veterinary drugs and foreign countries, and what my country needs to strengthen is: ① Innovation: Compared with our country, foreign platforms are broader, which can graft different products (vaccine) and are suitable for enterprises. Therefore, when my country is developing new products, it is better to build several such communication platforms, which can broaden perspectives and generate more new ideas; ②Promote sales: companies not only produce, but also use data to consolidate Existing position in the market; ③Improvement: Any benefit about products comes from the fundamental quality, and it is necessary to improve the GMP inspection system.

3. Network "win-win"

Q: How to create value for customers?

Sun Jinzhong: Take the layer customers as an example. The Internet in the layer field aims to create value for customers. It sets up multiple service points in the front line, which not only sells the customers needed (biological products, feed products, etc.), but also sells the customers' eggs. The purchase of chicken and egg rice forms a "dual-phase economy".

4. The Chinese market

Q: How does Merial view the Chinese market?

Li Wanmeng: ①China’s traditional consumption of pork will not change; ②Food consumption and poultry meat consumption will definitely increase; ③With the continuous improvement of people’s living standards and the aging population, the pet market will definitely increase; ④Rumination of cattle, sheep, etc. For animals, due to the "zero tariff" imports of New Zealand and Australia, it will have a great impact on the Chinese market.

5. The logical starting point should be considered from the perspective of the enterprise

Qin Dechao, General Manager of Qian Yuanhao: Regardless of the current system or the direction of future reforms, what is the logical starting point and legal basis for the approval of veterinary drugs, especially biological products?

Gu Hong, Director of the Department of Pharmaceutical Affairs, Ministry of Agriculture: We can only make a relatively achievable adjustment under the current legal framework of the "Regulations on Administration of Veterinary Drugs." It's not a matter of a few words, overnight. In the past two years, we have been working on the revision of the "Veterinary Drug Product Approval Number", which is expected to be released by the end of the year. The new "Veterinary Drug Product Approval Number" will have many regulations equivalent to the prevention and treatment system of human drugs, which will increase the protection of new veterinary drugs, and there will no longer be the situation of receiving a standard arbitrarily report, which can form a virtuous circle To promote technological innovation.

It is expected that the GMP standard for diagnostic products will be released before the end of the year, and now the main task is to make detailed changes to the language expression to make it more accurate. Its establishment is different from the current vaccine GMP requirements, and it reflects the biological products. Features and requirements for the plant. Has been established in the treatment of the entire veterinary drug standard management and registration review system. All in all, our aim must be to promote the development of the industry, to promote product quality and technological progress. We should not hinder the development of the industry because of our policies, and let the company guarantee the quality of the products to promote the development of the industry.

General Manager Qin Dechao evaluated and summarized the answers: On the road to reform in the future, the administration should adhere to the 12 words "enterprise perspective, close to the market, and protect innovation".

Yang Jinsong, deputy director of the China Institute of Veterinary Drugs, and vice chairman and secretary-general of the China Veterinary Drug Association, thanked the representatives who participated in the event. Industry enterprises are the theme, and Xieye will continue to serve the enterprises well and jointly achieve the development goals of the industry.